Biotechnology: How Analysts Read a Sector Built on Clinical Trial Odds
Produced with AI assistance. Reviewed by QuietTicker Editorial.

This lesson is educational only and does not constitute investment advice. Read the full Disclaimer before using anything here to make a decision about real money.
Biotechnology companies turn biology into medicine: antibodies, gene and cell therapies, RNA-based drugs, engineered proteins and vaccines. On a stock screen they sit inside healthcare next to hospitals and insurers, but they behave very differently. A hospital chain is valued on patient volumes and margins. Most listed biotech companies have no product on the market at all, so the share price is a bet on a pipeline of drug candidates that may or may not ever be approved. Learning to read this sector means learning to read that pipeline, the odds behind it, and the cash that has to carry it to the finish line.
Two very different kinds of biotech company
The sector splits into two groups. Commercial-stage companies such as Amgen, Regeneron and Vertex Pharmaceuticals sell approved medicines, report real revenue and are analysed much like other large healthcare businesses: sales growth by product, margins, patent life and how much of that profit is recycled into research. Clinical-stage companies are the larger group by count. They are pre-revenue or close to it, they report a net loss every quarter, and their valuation rests almost entirely on what the market thinks their experimental drugs are worth after adjusting for the chance of failure. When a small biotech name appears on a daily screen with a large move, it is usually a clinical-stage company reacting to news about one of those candidates.
The odds behind every pipeline
A drug candidate has to clear Phase I (safety in a small group), Phase II (early evidence that it works), Phase III (large confirmatory trials) and then a regulatory review. A study by the industry group BIO, Informa Pharma Intelligence and QLS Advisors, which tracked 12,728 phase transitions between 2011 and 2020, found that only 7.9% of candidates entering Phase I eventually won FDA approval. The hardest step was Phase II, where just 28.9% of programmes advanced. Phase III cleared 57.8% of the time, and 90.6% of applications filed with the regulator were approved. The same study put the average journey from Phase I to approval at 10.5 years.
Those averages hide wide gaps between disease areas. Oncology candidates had an overall likelihood of approval of only 5.3%, while therapies for rare diseases reached 17.0% and programmes that used biomarkers to pre-select patients reached 15.9%. For an analyst, this means the disease a company targets and the design of its trials matter as much as the science story in the investor presentation.
Why the share price can move 50% in a morning
Because so much value rides on a handful of trials, biotech stocks are exposed to binary events: a top-line data readout, an FDA decision date, an advisory committee vote, or a partner walking away from a licensing deal. A positive Phase III result can multiply a small company's market value overnight; a failed one can erase most of it, because the market removes the probability-weighted value of that drug in one step. These events sit at the top of what moves a stock, a point covered in more depth in The Catalyst Hierarchy. Regulatory output is also worth tracking at the sector level. The FDA's drug centre approved 50 novel drugs in 2024, and the list shows how many of those came from biologics and targeted therapies rather than traditional small-molecule pills.
Cash runway measured against the next catalyst
For a company with no revenue, the single most important balance-sheet number is how long its cash lasts. Runway is cash and short-term investments divided by the quarterly cash burn from operations, which you can read from the cash flow statement. EY's Beyond Borders 2025 report found that more than half of publicly traded biotechs finished 2024 with two years or less of cash runway, and that only eight of the 30 companies that listed in 2024 ended the year above their first-day closing price. Runway only means something when compared with the timing of the next major readout. A company that must raise money before its trial reports will usually sell new shares at a discount, diluting existing holders. That pattern is explained in Catalysts, Dilution Risk, and Red Flags.
A short checklist for a biotech name on your screen
Start with the stage: is this a company with approved products, or one living on a pipeline? Then identify the lead asset, its disease area and its current phase, and compare that phase with the historical success rates above. Look for the next dated catalyst in company filings or press releases, and set it against the months of cash left. Check the share count trend over the last few years, since steady growth in shares outstanding is the fingerprint of repeated equity raises. Finally, note who else is chasing the same target: a competitor with earlier or cleaner data can shrink the commercial opportunity even if a trial succeeds. None of these steps predicts a trial result, and nobody can do that reliably. What they do is show you how much risk the current price is already carrying.
